ProCE Banner Activity

SYNERGY: Custirsen in Poor-Prognosis mCRPC

Slideset Download
Conference Coverage
A retrospective exploratory analysis of the phase III SYNERGY trial shows that adding custirsen to docetaxel/prednisone selectively improves survival in treatment-naive patients with mCRPC and a poor prognosis.

Released: June 05, 2015

Expiration: June 03, 2016

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

AstraZeneca

Bayer Healthcare Pharma

Bristol Myers Squibb

Celgene

Genentech BioOncology

Incyte

Novartis Pharmaceuticals Corporation